A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Giorgio L. Colombo, Giovanni B. Gaeta, Mauro Viganò, Sergio di Matteo

Research output: Contribution to journalArticle

Abstract

Introduction: Chronic hepatitis B (CHB) is a prevalent disease associated with high morbidity, mortality, and impact on health care costs. Antiviral therapy is aimed at reducing hepatitis B virus replication in order to limit progressive liver disease and improve the natural history of the disease. This study estimates the cost-effectiveness of lamivudine, adefovir, telbivudine, entecavir, tenofovir, and pegylated interferon in patients with CHB. Methods: A Markov model was developed to evaluate the costs and benefits of antivirals in a cohort of patients with CHB (hepatitis B e antigen [HBeAg]-positive and HBeAg-negative) and cirrhosis over a period of 10 years. Different rescue therapies were considered, according to current guidelines. Data on efficacy and changes in quality of life were derived from clinicaltrials and epidemiological Italian data. Direct costs were assessed from the perspective of the Italian National Health Service.Results: Tenofovir was associated with lower costs and higher efficacy compared withentecavir, telbivudine, and adefovir, as shown by their incremental cost-effectiveness ratios(ICER) per quality-adjusted life-year (QALY) gained: tenofovir €30,959, entecavir €45,971,telbivudine €62,051, and adefovir €82,824. Even following 1 year of pegylated interferontherapy, tenofovir had a more favourable ICER per QALY gained compared with the other rescue options. The analysis of patients with cirrhosis confirms the results obtained with theCHB cohort though with higher ICERs. Sensitivity analyses on the main variables confirm theresults of the base case scenario. Conclusion: Within the Italian health care system, in patients with CHB, tenofovir is a cost- effective strategy compared with other available therapies. Public health care authoritieswould benefit from mathematical models designed to estimate the future burden of CHB infectiontogether with the impact of treatment and drug resistance.

Original languageEnglish
Pages (from-to)37-46
Number of pages10
JournalClinicoEconomics and Outcomes Research
Volume3
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Tenofovir
Chronic Hepatitis B
Italy
Cost-Benefit Analysis
Hepatitis B e Antigens
Quality-Adjusted Life Years
Costs and Cost Analysis
Antiviral Agents
Fibrosis
Delivery of Health Care
Therapeutics
Lamivudine
National Health Programs
Virus Replication
Drug Resistance
Hepatitis B virus
Health Care Costs
Interferons
Liver Diseases
Theoretical Models

Keywords

  • Adefovir
  • Chronic hepatitis B
  • Cost-effectiveness
  • Entecavir
  • Lamivudine
  • Markov model
  • Pegylated interferon
  • Telbivudine
  • Tenofovir

ASJC Scopus subject areas

  • Economics, Econometrics and Finance (miscellaneous)
  • Health Policy

Cite this

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. / Colombo, Giorgio L.; Gaeta, Giovanni B.; Viganò, Mauro; di Matteo, Sergio.

In: ClinicoEconomics and Outcomes Research, Vol. 3, No. 1, 2011, p. 37-46.

Research output: Contribution to journalArticle

Colombo, Giorgio L. ; Gaeta, Giovanni B. ; Viganò, Mauro ; di Matteo, Sergio. / A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. In: ClinicoEconomics and Outcomes Research. 2011 ; Vol. 3, No. 1. pp. 37-46.
@article{6a4b25d832504ccdb372c59672b1728a,
title = "A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy",
abstract = "Introduction: Chronic hepatitis B (CHB) is a prevalent disease associated with high morbidity, mortality, and impact on health care costs. Antiviral therapy is aimed at reducing hepatitis B virus replication in order to limit progressive liver disease and improve the natural history of the disease. This study estimates the cost-effectiveness of lamivudine, adefovir, telbivudine, entecavir, tenofovir, and pegylated interferon in patients with CHB. Methods: A Markov model was developed to evaluate the costs and benefits of antivirals in a cohort of patients with CHB (hepatitis B e antigen [HBeAg]-positive and HBeAg-negative) and cirrhosis over a period of 10 years. Different rescue therapies were considered, according to current guidelines. Data on efficacy and changes in quality of life were derived from clinicaltrials and epidemiological Italian data. Direct costs were assessed from the perspective of the Italian National Health Service.Results: Tenofovir was associated with lower costs and higher efficacy compared withentecavir, telbivudine, and adefovir, as shown by their incremental cost-effectiveness ratios(ICER) per quality-adjusted life-year (QALY) gained: tenofovir €30,959, entecavir €45,971,telbivudine €62,051, and adefovir €82,824. Even following 1 year of pegylated interferontherapy, tenofovir had a more favourable ICER per QALY gained compared with the other rescue options. The analysis of patients with cirrhosis confirms the results obtained with theCHB cohort though with higher ICERs. Sensitivity analyses on the main variables confirm theresults of the base case scenario. Conclusion: Within the Italian health care system, in patients with CHB, tenofovir is a cost- effective strategy compared with other available therapies. Public health care authoritieswould benefit from mathematical models designed to estimate the future burden of CHB infectiontogether with the impact of treatment and drug resistance.",
keywords = "Adefovir, Chronic hepatitis B, Cost-effectiveness, Entecavir, Lamivudine, Markov model, Pegylated interferon, Telbivudine, Tenofovir",
author = "Colombo, {Giorgio L.} and Gaeta, {Giovanni B.} and Mauro Vigan{\`o} and {di Matteo}, Sergio",
year = "2011",
doi = "10.2147/CEOR.S16655",
language = "English",
volume = "3",
pages = "37--46",
journal = "ClinicoEconomics and Outcomes Research",
issn = "1178-6981",
publisher = "Dove Medical Press Limited",
number = "1",

}

TY - JOUR

T1 - A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

AU - Colombo, Giorgio L.

AU - Gaeta, Giovanni B.

AU - Viganò, Mauro

AU - di Matteo, Sergio

PY - 2011

Y1 - 2011

N2 - Introduction: Chronic hepatitis B (CHB) is a prevalent disease associated with high morbidity, mortality, and impact on health care costs. Antiviral therapy is aimed at reducing hepatitis B virus replication in order to limit progressive liver disease and improve the natural history of the disease. This study estimates the cost-effectiveness of lamivudine, adefovir, telbivudine, entecavir, tenofovir, and pegylated interferon in patients with CHB. Methods: A Markov model was developed to evaluate the costs and benefits of antivirals in a cohort of patients with CHB (hepatitis B e antigen [HBeAg]-positive and HBeAg-negative) and cirrhosis over a period of 10 years. Different rescue therapies were considered, according to current guidelines. Data on efficacy and changes in quality of life were derived from clinicaltrials and epidemiological Italian data. Direct costs were assessed from the perspective of the Italian National Health Service.Results: Tenofovir was associated with lower costs and higher efficacy compared withentecavir, telbivudine, and adefovir, as shown by their incremental cost-effectiveness ratios(ICER) per quality-adjusted life-year (QALY) gained: tenofovir €30,959, entecavir €45,971,telbivudine €62,051, and adefovir €82,824. Even following 1 year of pegylated interferontherapy, tenofovir had a more favourable ICER per QALY gained compared with the other rescue options. The analysis of patients with cirrhosis confirms the results obtained with theCHB cohort though with higher ICERs. Sensitivity analyses on the main variables confirm theresults of the base case scenario. Conclusion: Within the Italian health care system, in patients with CHB, tenofovir is a cost- effective strategy compared with other available therapies. Public health care authoritieswould benefit from mathematical models designed to estimate the future burden of CHB infectiontogether with the impact of treatment and drug resistance.

AB - Introduction: Chronic hepatitis B (CHB) is a prevalent disease associated with high morbidity, mortality, and impact on health care costs. Antiviral therapy is aimed at reducing hepatitis B virus replication in order to limit progressive liver disease and improve the natural history of the disease. This study estimates the cost-effectiveness of lamivudine, adefovir, telbivudine, entecavir, tenofovir, and pegylated interferon in patients with CHB. Methods: A Markov model was developed to evaluate the costs and benefits of antivirals in a cohort of patients with CHB (hepatitis B e antigen [HBeAg]-positive and HBeAg-negative) and cirrhosis over a period of 10 years. Different rescue therapies were considered, according to current guidelines. Data on efficacy and changes in quality of life were derived from clinicaltrials and epidemiological Italian data. Direct costs were assessed from the perspective of the Italian National Health Service.Results: Tenofovir was associated with lower costs and higher efficacy compared withentecavir, telbivudine, and adefovir, as shown by their incremental cost-effectiveness ratios(ICER) per quality-adjusted life-year (QALY) gained: tenofovir €30,959, entecavir €45,971,telbivudine €62,051, and adefovir €82,824. Even following 1 year of pegylated interferontherapy, tenofovir had a more favourable ICER per QALY gained compared with the other rescue options. The analysis of patients with cirrhosis confirms the results obtained with theCHB cohort though with higher ICERs. Sensitivity analyses on the main variables confirm theresults of the base case scenario. Conclusion: Within the Italian health care system, in patients with CHB, tenofovir is a cost- effective strategy compared with other available therapies. Public health care authoritieswould benefit from mathematical models designed to estimate the future burden of CHB infectiontogether with the impact of treatment and drug resistance.

KW - Adefovir

KW - Chronic hepatitis B

KW - Cost-effectiveness

KW - Entecavir

KW - Lamivudine

KW - Markov model

KW - Pegylated interferon

KW - Telbivudine

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=79952977384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952977384&partnerID=8YFLogxK

U2 - 10.2147/CEOR.S16655

DO - 10.2147/CEOR.S16655

M3 - Article

C2 - 21935331

VL - 3

SP - 37

EP - 46

JO - ClinicoEconomics and Outcomes Research

JF - ClinicoEconomics and Outcomes Research

SN - 1178-6981

IS - 1

ER -